Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Sanae Yasuda"'
Autor:
Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, Bojan Lalovic, Taro Hihara, Taisuke Hoshi, Yasuhiro Funahashi, Jagadeesh Aluri, Osamu Takenaka, Sanae Yasuda, Ziad Hussein
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 954-969 (2024)
Abstract Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor (VEGF) receptors 1–3, fibroblast growth factor (FGF) receptors 1–4, platelet‐derived growth factor receptor‐α (PDGFRα), KIT, and
Externí odkaz:
https://doaj.org/article/fec72ea592c0472d9a7f71776803d395
Autor:
Hugo Geerts, Mike Walker, Rachel Rose, Silke Bergeler, Piet H. van derGraaf, Edgar Schuck, Akihiko Koyama, Sanae Yasuda, Ziad Hussein, Larisa Reyderman, Chad Swanson, Antonio Cabal
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 4, Pp 444-461 (2023)
Abstract Antibody‐mediated removal of aggregated β‐amyloid (Aβ) is the current, most clinically advanced potential disease‐modifying treatment approach for Alzheimer's disease. We describe a quantitative systems pharmacology (QSP) approach of
Externí odkaz:
https://doaj.org/article/d9e08080706b49e386d73cb4a04cf07d
Autor:
Seiichi Hayato, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, Ziad Hussein
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 12, Pp 1578-1591 (2022)
Abstract Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK) and PK/pharm
Externí odkaz:
https://doaj.org/article/a4225fc1516d43588fdf82ef59d7e7a2
Publikováno v:
Clinical Drug Investigation. 43:155-165
Autor:
Larisa Reyderman, Seiichi Hayato, Harsha Reddy, Osamu Takenaka, Sanae Yasuda, Chad J Swanson, Brian A Willis, Ziad Hussein
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Timothy J. Pluard, Ziad Husseiin, Sanae Yasuda, Erika Hamilton, Tarek Sahmoud, Oneeb Majid, Jianjun Alan Xiao, Dejan Juric, Lisa Cantagallo, Antonio Gualberto
Publikováno v:
Cancer Research. 81:PS12-15
RATIONALE: Addition of CDK 4/6 inhibitors to endocrine therapy has become standard for patients (pts) with ER+ and HER2- BC with improvements in overall survival. However, acquired resistance to front-line therapy is inevitable, and response to later
Autor:
Larisa Reyderman, Hisakuni Sekino, Naoki Uchida, Sari Shiba, Syuhei Inoue, Ken Kotaka, Kaeko Ishiba, Sanae Yasuda
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective: Perampanel is an approved anti-seizure drug. A new formulation of perampanel fine granules (FG; 1% perampanel) has been developed for patients who are unable to take tablets. Bioequivalence between the 4-mg FG and tablet perampanel formula
Autor:
Seiichi Hayato, Lora Hamuro, Maiko Nomoto, Shin Nishio, Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Toshio Shimizu, Hiroki Ikezawa, Yohei Otake, Takuma Miura, Yue Zhao, Li Zhu, Trixia Camacho, Calin Dan Dumitru, Sanae Yasuda
Publikováno v:
Journal of Clinical Oncology. 40:3090-3090
3090 Background: MORAb-202 is an ADC consisting of farletuzumab (an antibody that binds to FRα) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin B-cleavable linker. A phase 1 dose-escalation and expansion s
Publikováno v:
Clinical Pharmacology in Drug Development. 7:613-620
Perampanel is a highly selective, orally active, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that has been approved in many countries as a treatment for partial-onset seizures and primary generalized tonic
Autor:
W. George Lai, Min-Kun Chang, Cynthia A. Zamora, Maiko Nomoto, Y. Amy Siu, Peter Boyd, Edgar Schuck, Jagadeesh Aluri, Bhaskar Rege, Sanae Yasuda, Jim Ferry
Publikováno v:
British Journal of Clinical Pharmacology. 84:952-960
Aims Avatrombopag, a thrombopoietin receptor agonist, is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. We assessed three drug-drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers. Methods This w